Lipitor (Atorvastatin) News and Research

RSS

Atorvastatin (INN) (Lipitor, Pfizer), is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. Atorvastatin inhibits HMG-CoA reductase, the rate-determining enzyme located in hepatic tissue that produces mevalonate, a small molecule used in the synthesis of cholesterol and other mevalonate derivatives. This lowers the amount of cholesterol produced which in turn lowers the total amount of LDL cholesterol. Atorvastatin was first synthesized in 1985 by Bruce Roth while working at Parke-Davis Warner-Lambert Company (now Pfizer). With 2006 sales of US$12.9 billion, Lipitor is the largest-selling drug in the world.

Genomas awarded $1.2 million to develop DNA-guided system for management of statin therapy

Genomas, a biomedical company advancing DNA-guided medicine and personalized healthcare, has announced the award of a Fast-Track Phase I-II Small Business Innovation Research (SBIR) Grant totaling $1.2 million.

20 Mar 2008

Improving statins

Statin drugs are helping many people lower their cholesterol, but a new study in the February Journal of Lipid Research reveals that statins actually increase the production of another protein that limits their benefit.

8 Feb 2008

Statins taken after stroke may increase risk of hemorrhagic stroke

People taking cholesterol-lowering drugs such as atorvastatin after a stroke may be at an increased risk of hemorrhagic stroke, or bleeding in the brain, a risk not found in patients taking statins who have never had a stroke.

13 Dec 2007

Discovery of gene responsible for statin-induced muscle pain

Statins, the popular class of drugs used to lower cholesterol, are among the most commonly prescribed medications in developed countries.

27 Nov 2007

Benefits of statin drugs continue for years

Scientists in the UK have found that the benefits to the heart from taking statin drugs may last for years and are sustained even after the drugs are stopped.

11 Oct 2007

Low levels of good cholesterol risk for heart disease

According to the latest research reducing the amount of "bad cholesterol" (LDL - low density lipoprotein cholesterol) in the blood is incidental if the proper amount of "good cholesterol" (HDL - high density lipoprotein cholesterol) is not present.

3 Oct 2007

Potential new weight-loss wonder drug

More than 60 percent of American women are overweight, with nearly a third falling into the category of obese and at greater risk of cancer, heart disease and diabetes.

27 Sep 2007

New Pfizer HIV drug approved for sale in Europe

Drug giant Pfizer has been given approval for it's new HIV drug Celsentri to go on sale in Europe.

24 Sep 2007

Top five prescribed drugs

With a total nearly $5 billion, Lipitor, a cholesterol-reducing drug, ranked first in terms of total spending on prescription medicines by adults ages 18 to 64 in 2004, and another cholesterol-fighting drug, Zocor, ranked fourth at $2.3 billion, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

21 Sep 2007

Study looks at Atorvastatin and cholesterol

Scientists report in the October issue of the Journal of Lipid Research new details about how a drug used against heart disease helps to unclog blood vessels from an excess of cholesterol and fats.

18 Sep 2007

Novel angiogenic drugs could revolutionize treatment of peripheral arterial disease

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market entry of novel angiogenic agents, including a future blockbuster drug from Genzyme, could revolutionize symptomatic treatment of peripheral arterial disease (PAD).

12 Sep 2007

Stroke outcome improves when patients continue taking cholesterol-lowering drugs

A new study has illustrated the risks involved when statin treatment is discontinued after a stroke and shows an increased risk of death or dependency is present for up to 90 days.

29 Aug 2007

Cholesterol-lowering statins may also reduce the risk of Alzheimer's

Researchers in the United States say they believe cholesterol-lowering drugs may reduce the risk of Alzheimer's.

28 Aug 2007

Statin drugs may delay progressive artery damage in children

Starting statin therapy as young as age 8 safely and effectively delays the early artery damage caused by familial hypercholesterolemia (FH), according to a Dutch study reported in the Aug.7th print issue of Circulation: Journal of the American Heart Association.

7 Aug 2007

Coated aspirin doesn't guarantee problem-free use

Some people take aspirin without ever having a problem with their stomach. Others develop low-grade stomach pain or get an ulcer.

31 Jul 2007

Noninvasive ultrasound used to check health of carotid arteries

Specialists with the Strong Women's Heart Program are expanding a study that considers the effects of a statin drug on metabolic syndrome, a condition that increases women's risk for heart disease and stroke.

9 Jul 2007

Splitting high-dose pills and swallowing half could save cost

Slicing certain pills in half could slice a hefty amount off of America's prescription drug costs. While only some types of pills can be split safely, the practice could be used by millions of Americans – including many of those who take popular cholesterol-lowering drugs.

15 Jun 2007

Ranbaxy successfully challenges Atorvastatin patents in Norway

Ranbaxy Laboratories Limited (RLL) announced that the Norwegian Appeals Court today handed down a favorable decision for Ranbaxy in its case against Pfizer, involving key Norwegian patents on Atorvastatin in Norway.

1 Jun 2007

Single-tablet combination of atorvastatin and amlodipine for high blood pressure effective

Adults with high blood pressure and additional risk factors for heart disease may benefit more from taking one tablet rather than two, if their current treatment combines the lipid-lowering medication atorvastatin with the blood pressure-lowering medication amlodipine, researchers reported at the American Heart Association's 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke.

16 May 2007

Rosuvastatin well tolerated by a broad range of patients with dyslipidemia

The safety and tolerability of rosuvastatin were assessed using data from 16,876 patients who received rosuvastatin 5-40 mg in a multinational phase II/III/IIIb/IV program, representing 25,670 patient-years of continuous exposure to rosuvastatin. An integrated database, consisting of 33 trials whose databases were locked up to and including September 16, 2005, was used to examine adverse events and laboratory data.

9 May 2007